Overview

Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a single center, open label, randomized, parallel group single dose intravenous (i.v.) administration study. The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.
Phase:
Phase 1
Details
Lead Sponsor:
Mundipharma (China) Pharmaceutical Co. Ltd
Treatments:
Oxycodone